OctreoScan: Difference between revisions
(→Images) |
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
||
| (4 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
[[Image:Normal-octreoscan-004.jpg|right|300px]] | [[Image:Normal-octreoscan-004.jpg|right|300px]] | ||
{{SI}} | {{SI}} | ||
{{CMG}} | |||
__NOTOC__ | __NOTOC__ | ||
'''OctreoScan''' is a kit for the preparation of Indium In-111 pentetreotide, a diagnostic radiopharmaceutical. | |||
==Indications for OctreoScan imaging== | ==Indications for OctreoScan imaging== | ||
| Line 50: | Line 53: | ||
'''Normal OctreoScan''' | '''Normal OctreoScan''' | ||
[[Image:Normal-octreoscan-001.jpg]] | [[Image:Normal-octreoscan-001.jpg|left|thumb|400px|]] | ||
<br clear="left"/> | <br clear="left"/> | ||
[[Image:Normal-octreoscan-002.jpg]] | |||
[[Image:Normal-octreoscan-002.jpg|left|thumb|400px|]] | |||
<br clear="left"/> | <br clear="left"/> | ||
[[Image:Normal-octreoscan-003.jpg]] | |||
[[Image:Normal-octreoscan-003.jpg|left|thumb|400px|]] | |||
<br clear="left"/> | <br clear="left"/> | ||
[[Image:Normal-octreoscan-004.jpg]] | |||
[[Image:Normal-octreoscan-004.jpg|left|thumb|400px|]] | |||
<br clear="left"/> | <br clear="left"/> | ||
[[Image:Normal-octreoscan-005.jpg]] | |||
[[Image:Normal-octreoscan-005.jpg|left|thumb|400px|]] | |||
<br clear="left"/> | <br clear="left"/> | ||
[[Image:Normal-octreoscan-006.jpg]] | |||
[[Image:Normal-octreoscan-006.jpg|left|thumb|400px|]] | |||
<br clear="left"/> | <br clear="left"/> | ||
Latest revision as of 14:27, 20 August 2012
|
WikiDoc Resources for OctreoScan |
|
Articles |
|---|
|
Most recent articles on OctreoScan |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on OctreoScan at Clinical Trials.gov Clinical Trials on OctreoScan at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on OctreoScan
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on OctreoScan Discussion groups on OctreoScan Patient Handouts on OctreoScan Directions to Hospitals Treating OctreoScan Risk calculators and risk factors for OctreoScan
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for OctreoScan |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
OctreoScan is a kit for the preparation of Indium In-111 pentetreotide, a diagnostic radiopharmaceutical.
Indications for OctreoScan imaging
- Tumor evaluation
Patient preparation
- Bowel preparation with laxative and enema
- Discontinue octeotide therapy for 1 week prior the exam
Radiopharmaceutical
- In-111 OctreoScan
Dose and route of administration
- 6 mCi IV
- 4 hours (abdomen, pelvis)
- 24 hours (whole body)
Equipment
- Camera: Large field of view SPECT gamma camera
- Collimator: Medium-energy
- Window: 20% window around 173 and 245 KeV
Procedure
- 4 hours: Planar images of the abdomen and pelvis
- 24 hours: Planar images of the whole body. SPECT of regions of clinical concern.
Images
Normal OctreoScan
References
- Ziessman, Harvey A, O'Malley, Janis P, and Thrall, James M. Nuclear Medicine: The Requisites. 3rd ed. Philadelphia, Pennsylvania: Mosby, 2006. ISBN 0323029469